A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics

Ruggiero, Giovanni Maria; Laini, V.; Mauri, Massimo C.; Ferrari, V.; Clemente, Antonio; Lugo, Franco; Mantero, Mario; Redaelli, Gabriella; Zappulli, Daniela; Cavagnini, Francesco

doi:10.1016/s0278-5846(01)00174-9

Cited by 68 publications

(37 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One single-blinded comparison of amisulpride, fluoxetine and clomipramine in restricting AN has been published (Ruggiero et al, 2001). This is the only study (completed or ongoing) to evaluate amisulpride in this patient group.…”

Section: Randomized Controlled Trials Of Other Atypical Antipsychoticsmentioning

confidence: 99%

Atypical antipsychotics and anorexia nervosa: A review

McKnight

Park

2010

Euro Eating Disorders Rev

View full text Add to dashboard Cite

show abstract

Section: Randomized Controlled Trials Of Other Atypical Antipsychoticsmentioning

confidence: 99%

Atypical antipsychotics and anorexia nervosa: A review

McKnight

Park

2010

Euro Eating Disorders Rev

View full text Add to dashboard Cite

show abstract

“…One RCT compared low-dose (50 mg/d) amisulpride (a D 2 and D 3 receptor antagonist at higher doses, pre-synaptic antagonism at lower doses) to fluoxetine (mean dose 28 mg/d) and to clomipramine (mean dose 57.69 mg/d) in 35 in-patients with anorexia nervosa attending a weight restoration programme for 12 wk. Those given amisulpride had significantly greater weight gain but other illness features did not differ between groups (Ruggiero et al 2001).…”

Section: Antipsychotic Medicationsmentioning

confidence: 82%

Clinical psychopharmacology of eating disorders: a research update

Hay

Claudino

2011

Int. J. Neuropsychopharm.

111

View full text Add to dashboard Cite

The paper presents a critical review (with search date 2010) of the major psychotropic medications assessed in eating disorders, namely antipsychotics, antidepressants, mood-stabilizing medications, anxiolytic and other agents. The evidence of efficacy of drug treatments is mostly weak or moderate. In addition, attrition rates are usually higher than for psychotherapies. However, there is support for use of antidepressants, particularly high-dose fluoxetine in bulimia nervosa, and anticonvulsants (topiramate) for binge-eating disorder. Low-dose antipsychotic medication may be clinically useful as adjunct treatment in acute anorexia, particularly where there is high anxiety and obsessive eating-related ruminations and failure to engage, but more trials are needed. Drug therapies such as topiramate and anti-obesity medication may aid weight loss in obese or overweight patients with binge-eating disorder; however, common or potentially serious adverse effects limit their use.

show abstract

“…Clomipramine, a tricyclic antidepressant, appears to be less effective than amisulpride in treating anorexia nervosa (Crisp et al, 1987;Ruggiero et al, 2001). Amitriptyline…”

Section: Clomipraminementioning

confidence: 99%